ERBB2 and breast carcinoma: For instance, Wielgos et al. demonstrated the sensitivity of HER2+ homologous recombination (HR) proficient trastuzumab–resistant and parental breast cancer cells to the PARP inhibitors, veliparib and niraparib [7].